Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
- Resource Type
- Article
- Source
- The Lancet Gastroenterology & Hepatology; May 2023, Vol. 8 Issue: 5 p446-457, 12p
- Subject
- Language
- ISSN
- 24681253